The survival analysis indicated that both CD47 and ENO1 could be independently used as a predictive biomarker of prognosis in CRC patients, but the combination of CD47 and ENO1 has a better predictive performance than CD47 or ENO1 alone in CRC patients. This evidence concerns the gene ENO1 and colorectal carcinoma.